Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial.
BMC Cardiovasc Disord. 2017 Oct 30;17(1):274. doi: 10.1186/s12872-017-0707-y.
Moretti HD1, Colucci VJ2,3, Berry BD4,2.
1 Providence Saint Patrick Hospital, 500 W. Broadway St, Missoula, MT, 59802, USA. heidi.moretti at providence.org.
2 International Heart Institute of Montana, 500 W. Broadway, Missoula, MT, 59802, USA.
3 University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
4 Providence Saint Patrick Hospital, 500 W. Broadway St, Missoula, MT, 59802, USA.
10,000 IU of Vitamin D daily for 6 months raised levels by 49 ng
Cardiovascular category starts with the following
Cardiovascular category is associated with other categories: Diabetes 31, Omega-3 31 , Vitamin K 25 , Intervention 22 . Mortality 20 , Skin - Dark 18 , Magnesium 17 , Calcium 14 , Hypertension 14 , Trauma and surgery 13 , Stroke 13 , Kidney 12 , Metabolic Syndrome 11 , Seniors 10 , Pregnancy 8 as of Aug 2022
- Overview Cardiovascular and vitamin D
- CAD patients with low vitamin D were 1.6 X more likely to die – 27th meta-analysis Aug 2022
- Cardiovascular Disease is treated by Vitamin D - review Oct 2021
- Arterial Stiffness and Vitamins – only Vitamin D was found to help – meta-analysis Feb 2022
- Those raising Vitamin D above 30 ng were 1.4 X less likely to die of Heart Attack (VA 19 years) – Oct 2021
- Giving free vitamin D to every Iranian would pay for itself by just reducing CVD – Oct 2021
- Sudden Cardiac Arrest – 2.8 X higher risk if low vitamin D – 2019
- Peripheral arterial disease risk is 1.5X higher if low vitamin D – meta-analysis March 2018
- Heart attack ICU costs cut in half by Vitamin D – Oct 2018
- Cardiovascular disease 2.3 X more-likely if poor Vitamin D Receptor – Aug 2022
- Cholesterol is needed to produce both Vitamin D and Cortisol
- Overview Cholesterol and vitamin D
- Statins and vitamin D statins often reduce levels of vitamin D
- Statin side-effects are reduced by Vitamin D – US patent Application – April 2019
Note: Kansas City Cardiomyopathy Questionnaire ranges from 0 (worst, with poor chance of survival) to 100
Vitamin D status may influence heart failure (HF) patient outcomes by affecting b-type natriuretic peptide (BNP), parathyroid hormone (PTH), and enhancing cardiac contractility. Vitamin D deficiency is associated with morbidity and mortality in HF patients. The objective of this study was to determine if vitamin D3 at a comparatively high dose would replete 25-hydroxyvitamin D (25(OH)D) stores, improve BNP, PTH, cardiopulmonary function, reduce inflammatory markers, and improve quality of life (QOL) in HF patients.
This was a 6 month, parallel group, double-blind, placebo-controlled, single clinic center, randomized trial of supplemental vitamin D3 using a dose of 10,000 IU daily or placebo in 40 vitamin D deficient or insufficient (25(OH)D level ≤ 32 ng/ml) patients with stable New York Heart Association Class II-III HF in a specialty cardiology clinic. All variables were measured at baseline and 6 months. Values between the two treatment groups were assessed using Student's t-test or Mann-Whitney Test. Univariate analysis of covariance was conducted to adjust for variance in baseline 25(OH)D.
All results were adjusted for baseline 25(OH)D. The change in BNP from baseline was ∆ +30 ± 950 pg/ml for treatment vs. placebo ∆ +400 ± 1900 pg/ml, p = 0.003. 25(OH)D serum levels rose by 49 ± 32 ng/ml in the treatment group vs 4 ± 10 ng/ml in the placebo group, p < 0.001. PTH and exercise chronotropic response index improved in the treatment group vs placebo group, respectively, but both were attenuated by adjustment ( (∆-20 ± 20 pg/ml vs ∆ + 7 ± 53 pg/ml respectively (p = 0.01, adjusted p = 0.07)) and (∆ + 0.13 ± 0.26 vs. ∆-0.03 ± 02.9 respectively, p < 0.01, adjusted p = 0.17)). Other measured cardiopulmonary parameters remained unchanged. High sensitivity C-reactive protein (hsCRP) remained unchanged for women, but improved for men (∆-2 ± 4 treatment versus ∆2 ± 5 mg/L placebo, p = 0.05).
QOL scores, including composite overall and clinical summary scores significantly improved in treatment compared to placebo (∆ + 10 ± 15 versus -6 ± 15, p < 0.01 and ∆ + 8 ± 14 versus -8 ± 18, p = 0.01, respectively).
Repletion of 25(OH)D may improve QOL in HF patients and may help to normalize BNP, PTH, and hsCRP.
TRIAL REGISTRATION: Clinicaltrials.gov, NCT01636570 , First registered 3 July 2012.
PMID: 29084522 DOI: 10.1186/s12872-017-0707-y
|3000 visitors, last modified 13 Nov, 2017,